Welcome to our dedicated page for SPLASH BEVERAGE GROUP SEC filings (Ticker: SBEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Splash Beverage Group, Inc. filings document the regulatory record of a Nevada beverage operating company with common stock listed on NYSE American under SBEV. Its disclosures include Form 8-K material-event reports, periodic reporting notices, capital-structure items, shareholder voting matters, and governance updates.
The company's filings cover material agreements such as settlement amendments, board appointments and resignations, compensatory arrangements, equity-plan related grants, and amendments to its charter documents. Capital-structure disclosures include common stock registration details and the withdrawal of a Series A Preferred Stock designation. Reporting records also include annual-report timing disclosures and operating or financial-result categories tied to the company's beverage-brand portfolio.
SPLASH BEVERAGE GROUP, INC. (EDVA), now operating as Endovia Health Sciences, reports on U.S. federal moves toward rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act and explains how this supports its cannabinoid-focused strategy.
The company expects to submit a CannEpil® FDA "Z submission" and request a pre-submission conference in the coming week, aiming to advance its proprietary cannabinoid formulation through FDA pathways. It is also reviewing additional cannabinoid-based formulations and IP for potential licensing, acquisition or collaboration, and is working with capital partners to finalize expanded financing to support development and potential transactions. The rebrand to Endovia Health Sciences and ticker EDVA became effective on the NYSE American on August 24, 2026.
SPLASH BEVERAGE GROUP, INC. (symbol EDVA), whose registrant name in this report is Endovia Health Sciences, Inc., reported an unregistered equity financing. On August 25, 2026, the company sold and issued 510,951 shares of common stock to C/M Capital Master Fund, LP under a previously executed Securities Purchase Agreement dated September 19, 2025, generating gross proceeds of $107,610.62.
The shares were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b). The purchaser’s resales of these shares are covered by the company’s Form S-1 registration statement (File No. 333-298112), which became effective on August 24, 2026.
SPLASH BEVERAGE GROUP, INC. (SBEV), doing business here as Endovia Health Sciences, Inc., appointed Brady Cobb as Interim CEO and Michael Bondurant as Interim COO under new employment agreements dated August 20, 2026. Cobb’s base salary is $300,000 and Bondurant’s is $275,000.
Each executive can earn cash bonuses tied to increases in the company’s market capitalization: $50,000 if market cap rises by $5,000,000 by October 30, 2026; another $50,000 if it rises by $10,000,000 by December 31, 2026; and a further bonus equal to 3% of any additional market cap increase above that, capped so each executive’s total bonus does not exceed $300,000.
Cobb received 231,250 stock options and Bondurant 200,000 stock options. Subject to shareholder approval, each will also receive RSU grants representing 7% of a 20% fully diluted share pool previously approved by the board. If either is terminated without cause or a change of control transaction occurs, all of that executive’s unvested options and RSUs will vest.
Splash Beverage Group, Inc. (NYSE: SBEV), now operating as Endovia Health Sciences, Inc. (EDVA), reported that the U.S. FDA’s Center for Veterinary Medicine has established Investigational New Animal Drug (INAD) File No. 14145 for its CannEpil® veterinary development program. This is described as the first regulatory milestone under its collaboration agreement with Lupvindol Biosciences Ltd. and formally begins the FDA regulatory process for CannEpil® as an investigational veterinary pharmaceutical.
The company is initially pursuing CannEpil® for the management of cancer-related pain in companion animals, beginning with canine oncology, and plans to develop it under the FDA’s Minor Use / Minor Species designation and Conditional Approval pathway. CannEpil® is a pharmaceutical-grade oral liquid formulation of CBD and THC isolates manufactured under EU-GMP standards, for which the company holds exclusive global rights across licensed fields of use, including veterinary therapeutics.
The company also states it has rebranded to Endovia Health Sciences with a name and ticker change to EDVA effective on the NYSE American on August 24, 2026, reflecting a strategic focus on cannabinoid-based health sciences spanning FDA-regulated human and veterinary therapeutics and related consumer wellness and beverage opportunities. Extensive forward-looking statement disclosures highlight risks around capital needs, maintaining key licenses, completing required studies, obtaining regulatory authorizations, meeting debt obligations, and continued NYSE American listing compliance.
Splash Beverage Group, Inc. (SBEV) announced that its corporate name will change to Endovia Health Sciences, Inc. and its common stock will begin trading on the NYSE American under the new ticker “EDVA” effective at 9:30 a.m. Eastern Time on Monday, August 24, 2026. This name and ticker change reflects an ongoing strategic transformation from legacy beverage operations into a diversified cannabinoid-based health sciences platform focused on pharmaceutical, FDA-regulated human and veterinary therapeutics, and cannabinoid-based consumer wellness and beverage products.
The company highlighted progress in its CannEpil® program, including opening an Investigational New Animal Drug file with the FDA’s Center for Veterinary Medicine, and stated that existing stockholder rights and stock certificates remain unchanged, with no action required by shareholders. The press release also outlines significant risks, including the need to raise capital, maintain key licenses, meet debt obligations, obtain regulatory approvals and comply with NYSE American continued listing standards.
Splash Beverage Group, Inc. (SBEV) filed an amended resale registration statement covering up to 5,000,000 shares of common stock issuable to C/M Capital Master Fund, LP under an equity line of credit. These are resale shares to be sold by the investor; Splash is not selling shares directly under this prospectus.
The equity line could provide Splash with up to $30,782,793 in aggregate gross proceeds as it elects to sell shares to C/M, which may then resell them on the NYSE American. Common stock outstanding would rise from 6,412,521 to 11,412,521 shares if all registered shares are issued. The company plans to use any proceeds it receives for working capital, resolving disputes and payables, and general corporate purposes.
Splash is pivoting away from beverages toward regulated cannabinoid and wellness businesses, highlighted by an exclusive worldwide license for the CBD/THC product CannEpil® and a planned corporate name change to Endovia Health Sciences, Inc. A one-for-four reverse stock split took effect on July 24, 2026. The filing discloses substantial risks, including going-concern doubts, recurring large losses, negative equity, and potential NYSE American delisting if listing standards are not regained by January 29, 2027.
Splash Beverage Group, Inc. (SBEV) reported a sharply lower loss from continuing operations as it accelerates a strategic pivot into cannabinoid-based health sciences under the planned Endovia Health Sciences brand. For the six months ended June 30, 2026, loss from continuing operations was approximately $4 million, compared with approximately $11 million for the same period in 2025, an improvement of about $7 million, or 64%, driven primarily by cost-reduction initiatives and exiting alcoholic beverages.
Subsequent to June 30, 2026, the company entered an exclusive global license for CannEpil®, a pharmaceutical-grade cannabinoid platform initially developed for drug-resistant epilepsy, and expanded the license to veterinary applications targeting companion-animal oncology and chronic pain. Splash also signed a development and collaboration agreement with Lupvindol Biosciences Ltd. to lead scientific and FDA regulatory development of a CannEpil-based veterinary product through the FDA Center for Veterinary Medicine’s Investigational New Animal Drug and Conditional Approval pathways. The company is preparing to relaunch CannEpil in the UK, Ireland and select Latin American markets and expects its rebranding to Endovia Health Sciences, including a ticker change, to take effect on the NYSE American beginning August 24, 2026.
Splash Beverage Group, Inc. (SBEV), which is changing its name to Endovia Health Sciences, reported very limited operating activity for the quarter and six months ended June 30, 2026 as it transitions from legacy beverage brands to a cannabinoid health and wellness platform. Net revenues from continuing operations were essentially zero for 2026 compared with modest revenues in 2025, while the net loss from continuing operations narrowed to roughly $4.1 million for the first half of 2026 from $11.6 million a year earlier, helped by lower non‑cash debt discount amortization.
Total assets were only $1.1 million against total liabilities of $16.8 million, resulting in a stockholders’ deficit of about $15.7 million and a significant working capital deficit. Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern. To address liquidity, SBEV raised about $2.9 million in the first half of 2026 via an equity line of credit and converted debt into preferred and common stock, but carried $6.0 million of notes payable and $3.1 million of accrued interest at mid‑year. NYSE American has accepted the company’s compliance plan, giving it until January 29, 2027 to restore listing compliance, while subsequent‑event disclosures describe a CannEpil® cannabinoid license and a favorable proposed settlement sharply reducing a large revenue‑loan obligation.
Splash Beverage Group, Inc. notified that it will file its Form 10-Q for the quarter ended June 30, 2026 after the deadline, relying on Rule 12b-25 because the report could not be completed on time without unreasonable effort or expense. The delay stems from limited personnel and resources and additional time needed to review and prepare the quarter’s financial statements. The company expects to file the Form 10-Q within the 5-day extension period allowed for quarterly reports.
For the six months ended June 30, 2026, the company expects to report approximately $0 in revenues, compared with approximately $45,200 for the same period in 2025, citing a shift in its business model. It expects a loss from continuing operations of approximately $4 million, versus approximately $11 million a year earlier, an improvement of about $8 million due to significant cost reductions. These figures remain subject to revisions based on auditor review.